Search

Displaying results 1751 - 1760 of 2516 in total
  1. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. Bruton's tyrosine kinase plays a role in B cell r...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    Tyrosol

    go.drugbank.com/drugs/DB16855
    Experimental

    Synonyms: p-TyrosolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates
  3. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis. It is similar to ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  4. Drug

    Norclobazam

    go.drugbank.com/drugs/DB17092
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  5. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    Ziftomenib is a potent and highly selective menin inhibitor. This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation wh...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Redaporfin

    go.drugbank.com/drugs/DB17219
    Investigational

    Categories: P-glycoprotein substrates
  7. Drug

    P-BCMA-101

    go.drugbank.com/drugs/DB17371
    Investigational

    P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.

  8. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of a...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    Vimseltinib is a small molecule kinase inhibitor targeting colony-stimulating factor 1 receptor (CSF1R). It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. It is intended to provide a sa...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  10. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune thrombocytopenia (ITP). ITP is an autoimmune disorde...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates